Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV2-REP1 Gene Therapy for Choroideremia
NCT02553135Phase 2Completed
- Start
- Sep 2015
- Primary completion
- Feb 2018
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of timrepigene emparvovec in choroideremia. Started Sep 2015; status: completed.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremia
Beyond the preview
Go deeper on NCT02553135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553135.